Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10:2:100098.
doi: 10.1016/j.crpvbd.2022.100098. eCollection 2022.

Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms

Dejan Cvejić  1 , Norbert Mencke  2 , Gabriele Petry  3 , Hannah Ringeisen  3 , Hannah Hamburg  3 , Klaus Hellmann  1 , Donato Traversa  4 , Simone Morelli  4 , Angela Di Cesare  4 , Anastasia Diakou  5 , Róbert Farkas  6
Affiliations

Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms

Dejan Cvejić et al. Curr Res Parasitol Vector Borne Dis. .

Abstract

This paper describes a multicentric field study which has evaluated the safety and efficacy of a novel spot on formulation containing emodepside 2.04% w/v, praziquantel 8.14% w/v and tigolaner 9.79% w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 ml/kg body weight to privately owned cats infected with major intestinal nematodes (Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Uncinaria stenocephala) and/or cestodes (Dipylidium caninum, Taenia taeniaeformis) and/or lungworms (Aelurostrongylus abstrusus, Troglostrongylus brevior). A total of 219 cats from 26 veterinary clinics located in Albania, Greece, Hungary, Italy and Portugal were included in the study. Feces from the cats were examined on a single occasion between Study Day -7 and Day 0 (baseline) and post-treatment (i) twice between Day 7 and Day 14 (± 2) (for intestinal helminths) or (ii) twice between Day 21 (± 2) and Day 28 (± 2) (for lungworms). Cats were allocated into two groups at a ratio of 2:1 (Felpreva®: Profender®, i.e. a commercial control product containing emodepside and praziquantel). Cats infected with intestinal helminths were treated once on Day 0 (i) with Felpreva® (Group 1) or (ii) with Profender® (Group 2). Animals infected with lungworms received a second treatment with Profender® on Day 14 (± 2) regardless of group allocation. Faecal egg or larval count reduction for Felpreva® was 97.47% for intestinal nematodes and 96.80% for lungworms. No cats infected with cestodes at baseline resulted positive after treatment with Felpreva®. However, the low number of cats (n = 10) did not allow for a statistical analysis to be performed. Non-inferiority of Felpreva® compared to Profender® was statistically demonstrated for all target intestinal and respiratory parasites. No adverse events nor application site reactions were observed. These results show that the new topical combination product Felpreva® is highly safe and efficacious in treating infections caused by major species of feline intestinal nematodes, cestodes and lungworms under field conditions.

Keywords: Cat; Felpreva®; Intestinal helminths; Lungworms; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Gabriele Petry, Hannah Ringeisen, and Hannah Hamburg have conducted and funded the study and are employees of 10.13039/100014851Bayer Animal Health GmbH, an 10.13039/100012752Elanco Animal Health company. Dejan Cvejić and Klaus Hellmann are employees of Klifovet GmbH Munich, Germany. Norbert Mencke is an employee of Vetoquinol, Paris, France. Vetoquinol is the owner of the product Felpreva reported within this study. Róbert Farkas, Donato Traversa, Simone Morelli, Angela Di Cesare and Anastasia Diakou declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
See this image and copyright information in PMC

References

    1. Altreuther G., Buch J., Charles S.D., Davis W.L., Krieger K.J., Radeloff I. Field evaluation of the efficacy and safety of emodepside/praziquantel spot-on solution against naturally acquired nematode and cestode infections in domestic cats. Parasitology. 2005;97:S58–S64. doi: 10.1007/s00436-005-1445-0. - DOI - PubMed
    1. Beugnet F., Bourdeau P., Chalvet-Monfray K., Cozma V., Farkas R., Guillot J., et al. Parasites of domestic owned cats in Europe: co-infestations and risk factors. Parasit. Vectors. 2014;7:291. doi: 10.1186/1756-3305-7-291. - DOI - PMC - PubMed
    1. Beugnet F., Halos L., editors. Parasitoses and vector-borne diseases of cats. Merial; Lyon, France: 2015.
    1. Böhm C., Wolken S., Schnyder M., Basso W., Deplazes P., Di Cesare A., et al. Efficacy of emodepside/praziquantel spot-on (Profender®) against adult Aelurostrongylus abstrusus nematodes in experimentally infected cats. Parasitol. Res. 2015;114:S155–S164. doi: 10.1007/s00436-015-4521-0. - DOI - PubMed
    1. Bowman D.D., Hendrix C.M., Lindsay D.S., Barr S.C. Iowa State University. A Blackwell Science Company; USA: 2002. Feline clinical parasitology.

LinkOut - more resources